Nasdaq:ACAD
ACADIA PHARMACEUTICALS INC
A specialty pharma firm driving revenue growth from $517M to over $1B in 2024 while transitioning to strong profitability with a record $391M net income.
Key Metrics
Investment Thesis
Bull Case
Investors should consider buying ACAD due to the company's explosive revenue growth trajectory, doubling from 2022 to 2025, coupled with a massive swing to positive net income. The balance sheet remains solvent with over $177M in cash and equivalents despite heavy investing outflows, suggesting strategic long-term positioning rather than distress.
Bear Case
Potential buyers should avoid the stock if they are concerned about the large negative changes in accrued expenses (-$19.3M) and accounts payable (-$5.3M), which may signal liquidity tightening or aggressive accounting adjustments. The substantial non-cash adjustments of -$326.1M and other non-cash items of -$390M warrant scrutiny to ensure earnings quality is not being artificially inflated.
About ACADIA PHARMACEUTICALS INC
Acadia Pharmaceuticals is a specialty pharmaceutical manufacturer focused on developing and commercializing products for patients with unmet medical needs, primarily in the oncology space. The company serves markets across the United States through its branded generic and innovative drug portfolio. Key products include specialized formulations like Mycophenolic Acid and various oncology therapies.
Analysis
Management Discussion
Management has successfully navigated a turnaround, evidenced by the shift from a net loss in 2023 to a record $391M profit in 2025 while maintaining robust revenue growth of nearly $300M year-over-year. The significant cash outflow from investing activities (-$302.6M) and other investing (-$1.1B) suggests major strategic asset acquisitions or partnership investments, funded largely by financing inflows ($49.9M) and strong operating cash flow ($109.8M).
Industry Overview
The specialty pharmaceutical industry is characterized by high barriers to entry, complex regulatory landscapes, and a focus on niche markets with significant unmet needs. Companies in this sector must continuously innovate to extend product lifecycles and maintain pricing power against generic competition. Acadia operates within this dynamic environment, leveraging its specific expertise in oncology and immunosuppression therapies.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $517.2M | $726.4M | $957.8M | $1.07B |
| Cost of Revenue | $10.2M | $41.6M | $81.8M | $89.0M |
| Gross Profit | $507.1M | $684.8M | $876.0M | $982.5M |
| Operating Expenses | $730.7M | $758.2M | $645.2M | $877.7M |
| Operating Income | $-223.6M | $-73.4M | $230.8M | $104.8M |
| R&D | $361.6M | $351.6M | $303.2M | $328.8M |
| G&A | $369.1M | $406.6M | $488.4M | $548.9M |
| Stock-Based Comp | $68.2M | $66.4M | $67.0M | $52.1M |
| Depreciation | $2.0M | $1.5M | $920.0K | $871.0K |
| Amortization | $0 | $4.1M | $15.0M | $10.9M |
| Other OpEx | $-1.0K | $0 | $-146.5M | $0 |
| Non-Operating Income | $10.2M | $22.3M | $27.3M | $34.1M |
| Pre-Tax Income | $-213.4M | $-51.0M | $258.1M | $138.9M |
| Income Tax | $2.5M | $10.2M | $31.6M | $-252.1M |
| Continuing Ops | $-216.0M | $-61.3M | $226.5M | $391.0M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-216.0M | $-61.3M | $226.5M | $391.0M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-216.0M | $-61.3M | $226.5M | $391.0M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $507.9M | $616.1M | $938.3M | $1.06B |
| Cash & Equivalents | $114.8M | $188.7M | $319.6M | $177.7M |
| Accounts Receivable | $62.2M | $98.3M | $98.7M | $121.5M |
| Inventory | $11.6M | $40.4M | $91.7M | $111.4M |
| Other Current Assets | $319.3M | $288.8M | $428.3M | $651.6M |
| Long-Term Assets | $79.9M | $132.8M | $249.4M | $502.1M |
| PP&E (Net) | $6.0M | $4.6M | $4.2M | $7.5M |
| Operating Leases | $55.6M | $51.9M | $46.6M | $47.4M |
| Other LT Assets | $18.3M | $76.4M | $198.7M | $447.2M |
| Total Assets | $587.8M | $749.0M | $1.19B | $1.56B |
| Current Liabilities | $125.6M | $254.3M | $394.9M | $277.1M |
| Accounts Payable | $12.7M | $17.5M | $16.2M | $10.9M |
| Current Leases | $9.3M | $9.4M | $10.0M | $11.6M |
| Other Current Liab | $-9.3M | $-9.4M | $-10.0M | $-11.6M |
| Long-Term Liabilities | $61.8M | $62.9M | $60.1M | $59.7M |
| LT Operating Leases | $52.7M | $47.8M | $42.0M | $40.6M |
| Other LT Liab | $9.1M | $15.1M | $18.1M | $19.1M |
| Total Liabilities | $187.4M | $317.2M | $455.0M | $336.8M |
| Shareholders' Equity | $400.4M | $431.8M | $732.8M | $1.23B |
| Retained Earnings | $-2.37B | $-2.43B | $-2.20B | $-1.81B |
| AOCI | $-975.0K | $24.0K | $292.0K | $1.4M |
| Total L&E | $587.8M | $749.0M | $1.19B | $1.56B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-216.0M | $-61.3M | $226.5M | $391.0M |
| Non-Cash Adjustments | $76.8M | $-111.9M | $-209.7M | $-326.1M |
| Working Capital Changes | $25.1M | $189.8M | $141.0M | $45.0M |
| Cash from Operations | $-114.0M | $16.7M | $157.7M | $109.8M |
| Capital Expenditures | $0 | $50.0K | $523.0K | $4.7M |
| Cash from Investing | $73.2M | $32.0M | $-30.5M | $-302.6M |
| Cash from Financing | $8.2M | $25.1M | $6.8M | $49.9M |
| FX Effect | $6.0K | $-18.0K | $-94.0K | $26.0K |
| Net Change in Cash | $-32.6M | $73.8M | $133.9M | $-142.8M |
| Beginning Cash | $153.2M | $120.6M | $194.4M | $328.4M |
| Ending Cash | $120.6M | $194.4M | $328.4M | $185.5M |
Frequently Asked Questions
How does ACADIA PHARMACEUTICALS INC make money?
The company's revenue is driven by its Specialty Pharmaceuticals segment, which includes branded generics and innovative oncology products. A significant portion of cash flow adjustments relates to equity method investments, indicating exposure to affiliated biotech companies or strategic partnerships that contribute to the $138.9M equity profit.
What are the main risks for ACAD?
The pharmaceutical industry faces intense pricing pressure from payers and potential patent expirations that could erode the margins on specialty products. Regulatory changes in drug manufacturing or clinical trial outcomes for R&D projects like the $328.8M spent could impact future pipelines. The company carries a significant retained earnings deficit of -$1.81B, which investors must monitor against future profitability sustainability.
What is ACAD's competitive advantage?
Acadia possesses a robust intellectual property portfolio protecting its high-margin specialty formulations in oncology and immunosuppression. The company demonstrates efficient capital allocation with low capital expenditures relative to revenue, preserving cash for R&D. Strong management of working capital, evidenced by healthy accounts receivable turnover against modest payables, supports liquidity.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.